Discounts

Deadline Approaching: The 2015 Tissue Engineering Congress

Off

This three day meeting brings together the principles of engineering and life sciences in tissue development and regenerative medicine to discuss scientific research and developments of clinical applications from leading experts in the field. The newest research and developing technology will be discussed in an informal setting with plenty of networking opportunities

To find out more about this event or to register click here

A late registration fee applies after July 20th 2015

This event  has CPD accreditation

Who Should Attend
Anyone interested in the use of a combination of cells, engineering and materials methods, and suitable biochemical and physio-chemical factors to improve or replace biological functions would benefit from attending this event

This event has an open abstract session.
Abstracts can be submitted on any subject related to Regenerative Medicine or Tissue Engineering
Abstracts for poster presentation only can be submitted up to two weeks before the event
You can download the instructions for authors at www.euroscicon.com/ABSTRACTSUBMISSIONS.pdf
Registration includes entry to all the event, lunch and all refreshments, networking opportunities and access to exhibitions.

FEE  FOR  THREE  DAYS

 

REGISTRATION FEE

LATE REGISTRATION FEE

Standard

 £445 + VAT

 £545 + VAT

Academic

 £295 + VAT

 £395 + VAT

Student

 £195 + VAT

 £295 + VAT

If you do not want to attend the full three days you can also book single days at the following price

 

REGISTRATION FEE

 LATE REGISTRATION FEE

Standard

£195 + VAT

 £275 + VAT

Academic

£125 + VAT

 £195 + VAT

Student

£95 + VAT

 £145 + VAT

 

RSS Free Biotechnology & Pharmaceuticals Magazines

  • The State of Drug Pricing Reform in 2023
    Drug pricing reform in the U.S. is both further along than it’s been in years and stuck facing the same long odds that have frustrated past attempts at a major federal overhaul. If recent actions from Congress and the White House are any indication, pricing looks set to remain pharma’s greatest reputational risk of 2023 […]